Physician profile
Sam Hamade
NPI 1588752422
$634.94
in general payments reported to CMS, 2019-2025
17 companies · $464 in 2025
The $464 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.20 · 2020: $15.83 · 2022: $22.10 · 2023: $47.88 · 2024: $17.12 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $429 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.86 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $117.91 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Glaxosmithkline, LLC. | $66.79 | 2020-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $54.63 | 2024-2025 | |
| Verona Pharma, INC. | $33.83 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals Lp | $28.60 | 2019-2025 | Breztri |
| Pulmonx Corporation | $26.75 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Circassia INC. | $25.43 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.88 | 2025 | Dupixent |
| Genentech USA, INC. | $24.41 | 2025 | Xolair |
| Amgen INC. | $24.08 | 2025 | Tezspire |
| Mylan Specialty L.P. | $22.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.13 | 2023 | Ofev |
| Philips North America LLC | $19.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.84 | 2025 | Glassia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $15.60 | 2025 | Arikayce |
| Sunovion Pharmaceuticals INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Hamade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.